Chen, D., Odueyungbo, A., Csinady, E., Gearhart, L., Lehane, P., Cheu, M., Maho‐Vaillant, M., Prost‐Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M., Labeille, B., Picard‐Dahan, C., Paul, C., Richard, M., Bouaziz, J., Duvert‐Lehembre, S., Bernard, P., Caux, F., Alexandre, M., Ingen‐Housz‐Oro, S., Vabres, P., Delaporte, E., Quereux, G., Dupuy, A., Debarbieux, S., Avenel‐Audran, M., D'Incan, M., Bedane, C., Bénéton, N., Jullien, D., Dupin, N., Misery, L., Machet, L., Beylot‐Barry, M., Dereure, O., Sassolas, B., Benichou, J., Musette, P., Joly, P., & , (2020). rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect. British journal of dermatology, 182, 1111–1119. http://access.bl.uk/ark:/81055/vdc_100102515053.0x000060